Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 29;25(11):5917.
doi: 10.3390/ijms25115917.

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

Donghyun Seo  1 , Jun Hyeok Lim  2
Affiliations
Review

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

Donghyun Seo et al. Int J Mol Sci. .

Abstract

Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1-10% of these mutations. EGFR exon 20 insertions are less responsive to conventional tyrosine kinase inhibitors (TKIs), leading to the development of targeted agents. This review explores key therapeutic agents, such as Amivantamab, Mobocertinib, Poziotinib, Zipalertinib, and Sunvozertinib, which have shown promise in treating NSCLC with EGFR exon 20 insertions. Amivantamab, a bispecific antibody-targeting EGFR and c-MET, demonstrates significant efficacy, particularly when combined with chemotherapy. Mobocertinib, a TKI, selectively targets EGFR exon 20 mutations but faces limitations in efficacy. Poziotinib, another oral TKI, shows mixed results due to mutation-specific responses. Zipalertinib and Sunvozertinib have emerged as potent TKIs with promising clinical data. Despite these advances, challenges in overcoming resistance mutations and improving central nervous system penetration remain. Future research should focus on optimizing first-line combination therapies and enhancing diagnostic strategies for comprehensive mutation profiling.

Keywords: EGFR exon 20 insertion; amivantamab; mobocertinib; non-small-cell lung cancer; poziotinib; sunvozertinib; tyrosine kinase inhibitors; zipalertinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Jordan E.J., Kim H.R., Arcila M.E., Barron D., Chakravarty D., Gao J., Chang M.T., Ni A., Kundra R., Jonsson P. Prospective compre-hensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596–609. doi: 10.1158/2159-8290.CD-16-1337. - DOI - PMC - PubMed
    1. Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28:S24–S31. doi: 10.1038/onc.2009.198. - DOI - PMC - PubMed
    1. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical impli-cations. Lancet Oncol. 2012;13:e23–e31. doi: 10.1016/S1470-2045(11)70129-2. - DOI - PubMed
    1. Arcila M.E., Nafa K., Chaft J.E., Rekhtman N., Lau C., Reva B.A., Zakowski M.F., Kris M.G., Ladanyi M. EGFR exon 20 insertion mu-tations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 2013;12:220–229. doi: 10.1158/1535-7163.MCT-12-0620. - DOI - PMC - PubMed
    1. Oxnard G.R., Lo P.C., Nishino M., Dahlberg S.E., Lindeman N.I., Butaney M., Jackman D.M., Johnson B.E., Jänne P.A. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J. Thorac. Oncol. 2013;8:179–184. doi: 10.1097/JTO.0b013e3182779d18. - DOI - PMC - PubMed

MeSH terms

Grants and funding